TRAIL combinations: The new ‘trail’ for cancer therapy (Review)

Author：

ISSN： 1792-1074

Source： Oncology Letters, Vol.7, Iss.5, 2014-01, pp. : 1327-1332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

TRAIL receptor-targeted therapy

By Buchsbaum Donald J Zhou Tong LoBuglio Albert F

Future Oncology, Vol. 2, Iss. 4, 2006-08 ,pp. : 493-508

Future Medicine

Access to resources Recommend Favorite

TRAIL-receptor antibodies as a potential cancer treatment

By Buchsbaum Donald J Forero-Torres Andres LoBuglio Albert F

Future Oncology, Vol. 3, Iss. 4, 2007-08 ,pp. : 405-409

Future Medicine

Access to resources Recommend Favorite

Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 435-441

Spandidos Publications

Access to resources Recommend Favorite

Suppression of casein kinase 2 sensitizes tumor cells to antitumor TRAIL therapy by regulating the phosphorylation and localization of p65 in prostate cancer

Oncology Reports, Vol. 34, Iss. 3, 2015-01 ,pp. : 1599-1604

Spandidos Publications

Access to resources Recommend Favorite

Parthenolide enhances sensitivity of colorectal cancer cells to TRAIL by inducing death receptor 5 and promotes TRAIL-induced apoptosis

International Journal of Oncology, Vol. 46, Iss. 3, 2015-01 ,pp. : 1121-1130

Spandidos Publications

Access to resources Recommend Favorite